Skip to main content

AbbVie’s response to COVID-19

As COVID-19 continues to have an impact on our communities, AbbVie is focused on the health and safety of employees, health care professionals and patients and communities worldwide.

"During this challenging time, we are doing everything possible to ensure our employees remain safe, our patients receive their medicines, and assistance is available to help those most deeply impacted by the COVID-19 pandemic."  - Richard Gonzalez, CEO

AbbVie’s COVID-19 R&D efforts

As a global biopharmaceutical company, AbbVie is committed to addressing the COVID-19 public health crisis. We are collaborating with health authorities and institutions globally to identify potential treatments, including supporting clinical studies and basic research of our medicines. We’re also collaborating with industry, government, and academia, focusing on early science and discovery research

Learn more about our research and discovery efforts.

Protecting our employees in the workplace

Since the beginning of the pandemic, the health and safety of our employees has been our top priority. As an essential business, we’ve had employees working in our facilities throughout the crisis, and we’ve been proud that we’ve been able to continue to provide our patients with the critical medicines they depend on without any interruption.

Throughout the crisis, we’ve followed health and safety guidance from state and local health authorities, taking a phased and measured approach to returning more employees to AbbVie facilities, and have implemented a wide variety of safety measures for those employees who are returning to the workplace. We continue our enhanced safety protocols at all our sites.

Vaccination is the most effective way to keep people safe from COVID-19 and stop the spread of the virus. With vaccines widely available, we expect employees and third-party workers based at an AbbVie location who are able to receive a COVID-19 vaccination to do so before returning to the workplace.

As a global company, our policies vary by region. We constantly update our guidance in accordance to local and regional government health guidelines.

Providing flexibility and support

AbbVie encourages our employees to work with their managers and human resources team members for questions and to get the personalized support they need. Managers are empowered to provide employees with needed flexibility – as they were before the crisis.

Supply chain and production

We are continuing to closely monitor manufacturing and supply chain resources around the world to help ensure our patients continue to receive their medicines. We do not anticipate any disruption to our medicine supply for patients as a result of COVID-19.

Patients taking AbbVie medications

We understand your need to know more about the coronavirus. If you are on an AbbVie treatment, please speak with your doctor regarding any questions you may have. Your doctor can provide medical advice to address your individual needs.

Corporate giving

AbbVie has donated $35 million to help support underserved communities and health care systems working to address the impact of the COVID-19 global pandemic. AbbVie’s partners are:

  • International Medical Corps to help create capacity to treat patients at overburdened hospitals in the U.S. AbbVie’s donation will support the creation and operation of 20 mobile field hospitals to expand available triage at existing facilities, improve patient flow and keep COVID-19 patients separated from other patients. These standalone mobile field hospitals are being built in U.S. hotspots.
  • Direct Relief to provide equipment and supplies in the hardest-hit European countries. This support will enable the procurement and delivery of oxygen concentrators, ventilators and personal protective equipment to frontline health care workers and patients.
  • Feeding America to protect the most vulnerable, including the elderly, by enabling access to food and essential household supplies with minimal contact. Feeding America has created a new model of home delivery and drive-through service.
  • We continue to have a formal Grants & Donations application process for third sector groups and healthcare organisations to request funding for defined work and projects that qualify within our criteria. Please visit our Grants & Donations page to find out further information.

Healthcare providers

If you are a registered healthcare provider with questions about COVID-19 and AbbVie medications, patient assistance or adverse event reporting, please visit AbbVie's medical information website, www.abbviemedinfo.com.

Employee assistance

Protecting our employees 

For our employees and their family members impacted by coronavirus, the AbbVie Employee Assistance Fund, a part of the AbbVie Foundation, may be able to help. The Employee Relief Program provides short-term assistance with basic living expenses during unexpected events, including COVID-19.

If you are an employee that is being impacted by the COVID-19 pandemic and need assistance, click here to apply and for more information.

 

AbbVie health care workers as volunteers

AbbVie is committed to supporting the relief efforts of the COVID-19 pandemic crisis. As a global health care company, some of our employees may have the experience needed to support government and community organizations during this crisis.

The company provides a professional service policy for AbbVie employees with relevant medical, pharmaceutical, research and development, science, public health and public safety skills, knowledge, training, and experience who desire, are requested, or mandated to serve as volunteers during times of pandemic crisis.

AbbVie colleagues will continue to receive their full pay, benefits, and be able to return to their position after completing their service.

Clinical Trials impact

AbbVie has continued to make good progress with our development programs. Once the COVID-19 situation has stabilized, we will work to restart paused clinical studies. We do not expect the global pandemic to have long-term or significant impacts on our R&D programs. 

We are constantly monitoring and taking precautions to protect the safety of our study participants, clinical trial site staff and our employees. We will continue to evaluate any local support our study participants may require maintaining their safe involvement in our clinical trials.

Pharmaceutical Industry’s response

The Association of the British Pharmaceutical Industry (ABPI) is working closely with the Department of Health and Social Care and the NHS on how its members can best support the UK Government as plans evolve and we adapt to an ever-changing situation.

The ABPI, the Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), British Generic Manufacturers Association (BGMA) and the British In Vitro Diagnostic Association (BIVIDA) have issued a call to action on the UK life sciences industry’s commitment to fighting COVID-19 and supporting NHS patients. This is available here.

More detailed information on the industry response is available on the ABPI website here.

Resources

AbbVie Medical Information for healthcare providers
www.abbviemedinfo.com

World Health Organization Coronavirus disease (COVID-19) webpage
WHO website

ABPI
https://www.abpi.org.uk/

May 2022
UK-ABBV-220242